Clinical Trials Logo

Type 2 Diabetes clinical trials

View clinical trials related to Type 2 Diabetes.

Filter by:

NCT ID: NCT01901055 Terminated - Type 2 Diabetes Clinical Trials

Diabetes-Obstructive Sleep Apnea Treatment Trial

DOTT
Start date: February 13, 2014
Phase: N/A
Study type: Interventional

Diabetes self-management is important to help adults with type 2 diabetes achieve glucose control. Obstructive sleep apnea often co-exists with type 2 diabetes and may act as a barrier to diabetes self-management and glucose control. We will examine if treatment of obstructive sleep apnea with continuous positive airway pressure (CPAP), combined with diabetes education, results in improved diabetes self-management and glucose control.

NCT ID: NCT01891955 Completed - Type 2 Diabetes Clinical Trials

Alimentation and Diabetes in Lanzarote - ADILAN: a Pilot Trial

ADILAN
Start date: November 2013
Phase: N/A
Study type: Interventional

The purpose of this study is to compare two healthy diets (according to official Spanish guidelines) that have been shown to be effective in the treatment of type 2 diabetes in order to see if one is better than the other. Another goal is to test the hypothesis that food choice has metabolic effects that are independent of macro/micronutrient composition, fiber content, glycemic load and weight loss in the treatment of type 2 diabetes.

NCT ID: NCT01891786 Completed - Type 2 Diabetes Clinical Trials

Coronary Heart Disease Risk in Type 2 Diabetes

CORDIA
Start date: July 2013
Phase: N/A
Study type: Interventional

The primary objective of the CORDIA study is to use an effective evidence-based self-management intervention (SMI) for type 2 diabetes, with and without a novel test to give a personalised genetic and lifestyle risk of coronary heart disease, to examine their capacity to reduce the risk of coronary heart disease (CHD) and improve diabetes management in primary care patients with type 2 diabetes. The effect of these interventions on clinical, behavioural and psychological outcomes will be investigated.

NCT ID: NCT01886989 Completed - Type 2 Diabetes Clinical Trials

Cocoa Polyphenols and Postprandial Metabolism in Type 2 Diabetes

Start date: January 2012
Phase: N/A
Study type: Interventional

This study aims to investigate the postprandial effects of cocoa supplementation in glucose and lipids, and surrogate markers of atherosclerosis in patients with type 2 diabetes. The investigators aim to test the hypothesis that cocoa will lower high-fat mixed meal breakfast-induced postprandial rise of glucose, lipids and markers of atherosclerosis in patients with diabetes. Randomized cross-over controlled trial, in which participants will be assigned to the placebo or cocoa group with breakfast meal. Patients with type 2 diabetes(n=25) will qualify for the study. The participants will be asked to consume 2 cups cocoa or placebo beverage on 2 separate postprandial study days. Both groups will receive high-fat mixed meal breakfast on each day. Blood draws and blood pressure (including HDI) measurements will be conducted at fasting, 30 min, 1,2, 4 & 6 hours postprandial each day for 2 days.

NCT ID: NCT01884714 Completed - Obesity Clinical Trials

Exploring the Molecular Basis to Healthy Obesity: The Diabetes Risk Assessment Study

DRA
Start date: July 2011
Phase: N/A
Study type: Interventional

The purpose of this study is to better understand the genetic and metabolic differences in obese individuals with and without type 2 diabetes. It is expected that this research will help improve our understanding of the variability observed between obese and diabetic individuals.

NCT ID: NCT01884363 Completed - Type 2 Diabetes Clinical Trials

Walnut Consumption, Endothelial Function, and Biomarkers

Start date: June 2013
Phase: N/A
Study type: Interventional

This study will examine whether a twelve-week intervention with one ounce (28 g) per day of walnuts improves endothelial function measured non-invasively using finger probe (EndoPat-2000) in people with coronary heart disease or type 2 diabetes.

NCT ID: NCT01883258 Completed - Type 2 Diabetes Clinical Trials

Effect of Aerobic Interval Training on Cardiovascular Function in Type 2 Diabetes

Start date: May 2013
Phase: N/A
Study type: Interventional

The study objectives are: 1. To compare cardiovascular function in type 2 diabetes patients vs. healthy controls. 2. To compare the effect of 8 weeks of aerobic interval training versus continuous moderate exercise on cardiovascular function in adults with type 2 diabetes. 3. To examine the mechanisms underlying the exercise-related changes in cardiovascular function. The investigators hypothesize that compared to continuous moderate intensity exercise training, interval training will be more effective in improving cardiovascular function in adults with type 2 diabetes.

NCT ID: NCT01882907 Completed - Type 2 Diabetes Clinical Trials

Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes

Start date: December 2009
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare the effect of 16 weeks treatment with vildagliptin to pioglitazone as add-on the therapy to metformin in patients with type 2 diabetes inadequately controlled with metformin monotherapy.

NCT ID: NCT01880827 Completed - Obesity Clinical Trials

Splanchnic Blood Redistribution After Incretin Hormone Infusion and Obesity Surgery

GIP-PET
Start date: January 2013
Phase: Phase 1
Study type: Interventional

Obesity is a worldwide problem and leads to multiple metabolic and endocrinological problems. Bariatric surgeries are a growing field as a treatment choice for morbid obesity (BMI > 35 kg/m2). Clinical and research evidence shows that shortly after RYGB, T2DM resolves with improving glucose tolerance. Foregut hypothesis behind bariatric surgeries postulate, that bypassed portions of intestine contain a substance, that acts as an anti-incretin, ie. to counteract metabolically favourable incretins. In view of the recent studies, it may be that GIP is really the anti-incretin behind this hypothesis. The current study is conducted to investigate the vasoactive roles of the GIP. The investigators aim to show that GIP is the major contributor to the blood flow and tissue blood volume observed in postprandial state.

NCT ID: NCT01877603 Completed - Type 2 Diabetes Clinical Trials

The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes

Start date: July 2013
Phase: N/A
Study type: Observational

Irisin is a signaling protein that is released into the blood from skeletal muscle after proteolysis of the membrane protein FNDC5 . FNDC5, encoded by the Fndc5 gene. Irisin activity on subcutaneous white adipose tissue, both in culture and in vivo, stimulated UCP1 expression and induction of brown adipocytes in white adipose tissue depots, a process known as white fat ''browning''. Irisin increases total energy expenditure in animal models, and irisin expression in mice fed a high fat diet resulted in a significant improvement in glucose tolerance and a reduction in fasting insulin levels. Collectively, these data suggest that decreased serum irisin levels may be associated with the development of insulin resistance and Type 2 diabetes. Indeed, some studies showed that irisin levels were decreased in newly diagnosed Type 2 diabetes. Endothelial dysfunction is an early physiological event in atherosclerosis. However, to date, no data are available on the relationship between circulating irisin and endothelial dysfunction in diabetes. Therefore, the investigators hypothesized that circulating irisin level is associated with endothelial dysfunction.